• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Cosentyx Rhuem Reps come on over!

Quote

anonymous

Guest
Come on over to Gilead! We are building out and plan to put around 150 in the field this summer to break Abbvie's rule. We'd like rock star reps to come over. We know most of you don't have the experience we are looking for but some of you might!

We understand that your incentive program doesn't differentiate between high and low performers, but apply anyway. We have detailed market share data and will get back in touch with those we know can sell. Force ranking is what we do!

We will have a performance based IC. If you don't perform, you won't make a cent. If you do, you'll make $90K + on bonus, $50k a year in RSUs and we offer the highest salaries in the industry. Many of you are going to be cashing in on some RSU early this year- if you have what it takes maybe you can really make some mad cash.

We only want performers who can successfully navigate double step edits, work Specialty Pharmacies without getting in trouble, and who don't complain. If you believe you deserve a mini-van or want to know our maternity leave policies, don't bother.

Jobs are posted. We will get back in touch with who we deem worthy.

Cosentyx is about to really get its ass kicked. IL-23 and JAK's coming to take your share. You aren't' even the best IL-17 and an even better one is coming soon. Upa will be a battle because of their contracting. We will pay those who beat them. This is your one chance to get with a real company. We only will take the best of the best.
 












Heard you got Ed G over there now. The IC will probably end up just as f’d up over there. At least JK tried to fight it. EG just doesn’t want to hear any complaining.
Still wouldn’t be surprised if a big group headed over there...if they will pay. Tough to give up being the leader in nRX for PSA to go sell the 4th JAK that has worse efficacy than Abbvie’s new one. While it may have a better safety profile in the data, the FDA will probably give it a black box, too. I don’t see them getting very good coverage, either. AbbVie and bundle rebates with Humira.
 




anonymous said:
Heard you got Ed G over there now. The IC will probably end up just as f’d up over there. At least JK tried to fight it. EG just doesn’t want to hear any complaining.
Still wouldn’t be surprised if a big group headed over there...if they will pay. Tough to give up being the leader in nRX for PSA to go sell the 4th JAK that has worse efficacy than Abbvie’s new one. While it may have a better safety profile in the data, the FDA will probably give it a black box, too. I don’t see them getting very good coverage, either. AbbVie and bundle rebates with Humira.
Click to expand...

the things you will probably complain about regarding our IC is the same complaints at every big pharma company. Focus on being a better rep and you will make plenty of money here. Ed is a good man and Gilead is lucky to have him. Jennifer was completely clueless.
 




anonymous said:
the things you will probably complain about regarding our IC is the same complaints at every big pharma company. Focus on being a better rep and you will make plenty of money here. Ed is a good man and Gilead is lucky to have him. Jennifer was completely clueless.
Click to expand...


You clearly don't understand it, then. None are perfect, but this is the most screwed up I've ever seen. JK at least understood it and tried to fight to fix it. In all of my years in this industry I have never seen a group of people - reps and leadership - so clueless about how they get paid. Morons all concerned about the accuracy of the data. That is so far from the biggest problem.
 




anonymous said:
You clearly don't understand it, then. None are perfect, but this is the most screwed up I've ever seen. JK at least understood it and tried to fight to fix it. In all of my years in this industry I have never seen a group of people - reps and leadership - so clueless about how they get paid. Morons all concerned about the accuracy of the data. That is so far from the biggest problem.
Click to expand...

Seems easy to me we are paid on a goal of volume and a marketshare goal. Never been less than top 20%...love it here
 




anonymous said:
You clearly don't understand it, then. None are perfect, but this is the most screwed up I've ever seen. JK at least understood it and tried to fight to fix it. In all of my years in this industry I have never seen a group of people - reps and leadership - so clueless about how they get paid. Morons all concerned about the accuracy of the data. That is so far from the biggest problem.
Click to expand...

I know we are underpaid not sure how they come up with these goals
 




anonymous said:
Seems easy to me we are paid on a goal of volume and a marketshare goal. Never been less than top 20%...love it here
Click to expand...

Omg. And how do they come up with those? THAT is the problem. Do you understand fair share goaling? Do you understand that when it comes to the volume goal that everyone is treated as if they have the same biologic market, despite the huge variances? Ask your manager for the spreadsheet with goals. People with higher shares have growth rates (not number of scripts to hit goal) that are higher, often MUCH higher than those with lower share.

If you don’t know how they come up with goals, its on you to ask. Sadly, your manager probably doesn’t get it, either. As the other poster said, this group is so clueless when it comes to their money.
 




anonymous said:
Omg. And how do they come up with those? THAT is the problem. Do you understand fair share goaling? Do you understand that when it comes to the volume goal that everyone is treated as if they have the same biologic market, despite the huge variances? Ask your manager for the spreadsheet with goals. People with higher shares have growth rates (not number of scripts to hit goal) that are higher, often MUCH higher than those with lower share.

If you don’t know how they come up with goals, its on you to ask. Sadly, your manager probably doesn’t get it, either. As the other poster said, this group is so clueless when it comes to their money.
Click to expand...

people with lower shares have higher growth rates. Thus territories that can never catch up. Talk about being clueless....

Carry on
 




This is an enlightening thread. I'm in a different division and we have the same complaints about ic yet we are told cosentyx and oncology are the best places to be at nvs. They treat you the best. Seems as though nvs cant figure out a fair way to pay ppl no matter what division. Thanks for the insight. I'm out of this place!
 




Heard at least 2 more managers in the East will be leaving soon to Gilead. Talk of exciting culture...haha heard that before. Hope it works out for them. Saw job postings for reps but haven't heard of any being interviewed yet.
 




anonymous said:
Heard at least 2 more managers in the East will be leaving soon to Gilead. Talk of exciting culture...haha heard that before. Hope it works out for them. Saw job postings for reps but haven't heard of any being interviewed yet.
Click to expand...
Might be hard to get in at Gilead - heard the pay and stock is much better at Biotech Companies. I have a friend at Gilead and know they are top payers in industry.
 




anonymous said:
people with lower shares have higher growth rates. Thus territories that can never catch up. Talk about being clueless....

Carry on
Click to expand...

Do you even read your ic playbook or look at the goals for your area? Your growth rate has been determined 75% by volume and 25% by share. That is why it says low VOLUME and low share have higher goals. That adjustment for share was just instituted last year. Before that it was only volume. For IC 2 now, it’s 80% volume, 15% share (and only PsA share now) and 5% biomarket. The biomarket component is basically an attempt to lock people into their current ranking of biomarket size.
If you have 2 territories with the same share, the one with the bigger biomarket gets a lower growth rate because their volume of Cosentyx is higher. This is not rocket science. It’s pretty basic math.
Clueless is an understatement for you.
Gilead should think twice before paying a bunch of money for people that either don’t even bother to read about how they are paid or can’t comprehend the basic math.
 




anonymous said:
Do you even read your ic playbook or look at the goals for your area? Your growth rate has been determined 75% by volume and 25% by share. That is why it says low VOLUME and low share have higher goals. That adjustment for share was just instituted last year. Before that it was only volume. For IC 2 now, it’s 80% volume, 15% share (and only PsA share now) and 5% biomarket. The biomarket component is basically an attempt to lock people into their current ranking of biomarket size.
If you have 2 territories with the same share, the one with the bigger biomarket gets a lower growth rate because their volume of Cosentyx is higher. This is not rocket science. It’s pretty basic math.
Clueless is an understatement for you.
Gilead should think twice before paying a bunch of money for people that either don’t even bother to read about how they are paid or can’t comprehend the basic math.
Click to expand...


This is 100% correct.
 




anonymous said:
Do you even read your ic playbook or look at the goals for your area? Your growth rate has been determined 75% by volume and 25% by share. That is why it says low VOLUME and low share have higher goals. That adjustment for share was just instituted last year. Before that it was only volume. For IC 2 now, it’s 80% volume, 15% share (and only PsA share now) and 5% biomarket. The biomarket component is basically an attempt to lock people into their current ranking of biomarket size.
If you have 2 territories with the same share, the one with the bigger biomarket gets a lower growth rate because their volume of Cosentyx is higher. This is not rocket science. It’s pretty basic math.
Clueless is an understatement for you.
Gilead should think twice before paying a bunch of money for people that either don’t even bother to read about how they are paid or can’t comprehend the basic math.
Click to expand...

Same as it has always been- lower volume and lower share territories get higher goals and can never catch up to the larger territories. "Fair share" goals aren't fair and aren't done at Gilead.

The real reason for responding to these idiots arguing- I was told that the director in the East- Ed didn't go to Gilead. He went to a different company. No one has announced that they are going to Gilead- at least yet.
 




anonymous said:
Same as it has always been- lower volume and lower share territories get higher goals and can never catch up to the larger territories. "Fair share" goals aren't fair and aren't done at Gilead.

The real reason for responding to these idiots arguing- I was told that the director in the East- Ed didn't go to Gilead. He went to a different company. No one has announced that they are going to Gilead- at least yet.
Click to expand...


Not the same as it’s always been. They used to use high volume (not share) as an adjustment factor and call it a share adjustment factor - double whammy, before the 75/25 mentioned in earlier post. Yes, it’s very unfair.
 




I'm not to worried about people from this division leaving to Gilead. They force rank and our snowflakes that continue to bitch and whine about everything would never last a week in a performance based environment. Novartis- big pharma- is perfect place for the majority of our detail men and women that can't sell but are good at "tell".
 








anonymous said:
I'm not to worried about people from this division leaving to Gilead. They force rank and our snowflakes that continue to bitch and whine about everything would never last a week in a performance based environment. Novartis- big pharma- is perfect place for the majority of our detail men and women that can't sell but are good at "tell".
Click to expand...

Everyone pretends to be a salesmen in Pharma, everyone. Pharma is not even close to sales quit fooling yourselves.
 




Top Bottom
Back
Quote